Oncotype Dx use and its relationship with chemotherapy administration in the general population

被引：0
|
作者：
Chavez-MacGregor, Mariana [1 ]
Niu, Jiangong [1 ]
Smith, Benjamin [1 ]
Zhao, Hui [1 ]
Buchholz, Thomas A. [1 ]
Giordano, Sharon H. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-05
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Determine the relationship between Ki 67 and Oncotype DX.
    Mulla, Nasser
    Alnouri, Anwar
    Al Majed, Muneera Majed
    Aleynikova, Olga
    Pelmus, Manuela
    Florea, Anca
    Panasci, Lawrence C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Utilization of Oncotype DX in an Inner City Population: Race or Place?
    Guth, Amber A.
    Fineberg, Susan
    Fei, Kezhen
    Franco, Rebeca
    Bickell, Nina A.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2013, 2013
  • [23] Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results
    Kamaljeet Singh
    Xin He
    Elizabeth T. Kalife
    Shahrzad Ehdaivand
    Yihong Wang
    C. James Sung
    Breast Cancer Research and Treatment, 2018, 168 : 29 - 34
  • [24] Race, Oncotype DX, and other characteristics in a highly screened population
    Chun, Jennifer
    Schnabel, Freya Ruth
    Schwartz, Shira
    Billig, Jessica
    Kern, Elizabeth
    Hiotis, Karen
    Axelrod, Deborah M.
    Guth, Amber
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [25] Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
    Kim, Jinkyoung
    Kim, Aeree
    Kim, Chungyeul
    ONCOLOGY LETTERS, 2019, 17 (02) : 1812 - 1818
  • [26] Oncotype Dx assay impact on decision making chemotherapy in breast cancer
    Muhibullah, N.
    Khout, H.
    Whisker, L.
    Gutteridge, E.
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 29 - 29
  • [27] Evaluation of variables that may impact chemotherapy (CT) administration after determination of Oncotype DX (ODX) recurrence score (RS)
    Bowen, Kristina E.
    Gilmore, James W.
    Szabo, Stephen
    Haislip, Sally
    Hassell, Robert
    Cooper, Joseph
    Richardson, Steve
    Fitzgerald, Meghan
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Current controversies in the use of Oncotype DX in early breast cancer
    Giachetti, Pier Paolo M. Berton
    Schianca, Ambra Carnevale
    Trapani, Dario
    Marra, Antonio
    Toss, Angela
    Marchio, Caterina
    Dieci, Maria Vittoria
    Gentilini, Oreste Davide
    Criscitiello, Carmen
    Kalinsky, Kevin
    Sparano, Joseph A.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2025, 135
  • [29] ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY
    Roberts, Megan C.
    Bryson, Amy
    Weinberger, Morris
    Dusetzina, Stacie B.
    Dinan, Michaela A.
    Reeder-Hayes, Katherine
    Wheeler, Stephanie B.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2016, 32 (05) : 355 - 361
  • [30] Evaluation of variables that may impact the use of Oncotype DX testing
    Szabo, Stephen
    Gilmore, James W.
    Haislip, Sally
    Hassell, Robert
    Cooper, Joseph
    Richardson, Steve
    Fitzgerald, Meghan
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345